Monitoring Atherosclerosis Regression, Plaque Stabilization, and Cardiovascular Risk Using a Novel Method to Quantify Oxidized Phospholipids

Background

It is known that oxidized phospholipids are pre-inflammatory and pro-atherogenic and that high-density lipoproteins (HDL)—or its lipoprotein also called apolipoprotein-A—is involved in mediating reverse cholesterol transport. Currently there is no accepted method for high-throughput measurement of reverse cholesterol transport or reverse-oxidized phospholipid transport.

Technology Description

This invention provides a high-throughput in vitro assay [enzyme linked immunoassay] to measure oxidized phospholipds on HDL, HDL-related lipoproteins, and mimetics as a method of estimating reverse oxidized phospholipid transport or plaque stabilization and regression. This technology has been optimized to quantitatively estimate reverse oxidized phospholipid transport and monitor plaque stabilization and regression in studies of rabbits, non-human primates, and human populations.

Applications

Offers a high-throughput method to monitor atherosclerosis regression, plaque stabilization, and cardiovascular risk.

Advantages

• Fully developed technology, having been demonstrated in multiple studies.
• Technology can be adopted to use other antibodies of high affinity to oxidized phospholipids.
• Suitable for monitoring the effect of therapeutic intervention studies of patient or model populations.

Related Materials

1. Arai K, Luke MM, Koschinsky ML, Miller ER, Pullinger CR, Witztum JL, Kane JP, Tsimikas S. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis. 2010 Apr;209(2):498-503.
2. Ahmadi N, Tsimikas S, Hajsadeghi F, Saeed A, Nabavi V, Bevinal MA, Kadakia J, Flores F, Ebrahimi R, Budoff MJ. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol. 2010 Feb 15;105(4):459-66.

Patent Status